Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 550 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glycemic Control Clear all
Terminated Not applicable Interventional Results available

Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery

NCT00328094
View directory record Official record
Conditions
Peripheral Vascular Disease, Abdominal Aortic Aneurysm
Interventions
continuous intravenous insulin infusion
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 5, 2026, 2:58 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

NCT04696159
View directory record Official record
Conditions
Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis
Interventions
Pyloromyotomy
Procedure
Lead sponsor
Matthew Allemang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 5, 2026, 2:58 PM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 5, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

Ultrasound Effects on Glycemic Control in T2DM

NCT05354947
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Ultrasound Delivery
Device
Lead sponsor
Yale University
Other
Eligibility
21 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes

NCT00106808
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Muraglitazar, Pioglitazone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Columbiana, Alabama • Madison, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes

NCT02065310
View directory record Official record
Conditions
Diabetes
Interventions
N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Sep 5, 2026, 2:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control

NCT02190669
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
exercise
Other
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Yoga as a Complementary Therapy for Adults With Type 2 Diabetes

NCT02607566
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Yoga, Standard Exercise Program
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Not applicable Interventional

The Effects of a Pre-packaged, Portion Controlled Meal Plan on Type 2 Diabetes and Glycemic Control: A Comparison Study

NCT01260337
View directory record Official record
Conditions
Obesity
Interventions
Portion controlled diet, Diabetes Support and Education
Behavioral · Other
Lead sponsor
Temple University
Other
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2013 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

NCT02182895
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 5, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

NCT07502495
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
icovamenib 100mg, Placebo
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Canoga Park, California • Fountain Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

NCT00423501
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 5, 2026, 2:58 PM EDT
Not yet recruiting Not applicable Interventional

Continuous Glucose Monitoring in Metabolic Surgery

NCT07095972
View directory record Official record
Conditions
Obesity (Disorder)
Interventions
Abbot Freestyle Libre CGM
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 5, 2026, 2:58 PM EDT
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 5, 2026, 2:58 PM EDT
Recruiting Not applicable Interventional

Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes

NCT06297980
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycaemia Due to Type 1 Diabetes Mellitus, Menstruation Disturbances
Interventions
Personalized modifications to treatment to address menstrual cycle effects on glycemia
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

NCT02435277
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Mid Metformin, High Metformin, Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Not applicable Interventional Results available

Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes

NCT04924400
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CHIP Program, Usual Care
Behavioral
Lead sponsor
Thomas Morland
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

NCT01046422
View directory record Official record
Conditions
Diabetes Type 2
Interventions
BMS-770767, Placebo, Metformin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Lomita, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

NCT00673231
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Fresno, California • Greenbrae, California • Roswell, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 4 Interventional

Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER)

NCT05922033
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions
Patient-led Insulin (intervention group), Provider-led Insulin (standard care)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Not applicable Interventional

Randomized Trial of Peer Led Education-Project Dulce

NCT01238289
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Peer Education, Control
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 5, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

NCT00800176
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO4998452
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 5, 2026, 2:58 PM EDT